Part D Coverage Gap Discounts Deepened To 70% In Budget Bill
Change, which could have multi-billion dollar impact on some large companies over 10 years, is framed as way to lower premiums in Medicare Part D.
You may also be interested in...
Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.
PhRMA pushing for legislation to address upcoming surge in Medicare Part D out-of-pocket spending requirements and reverse the recently-enacted increase in the discount on branded drugs in the coverage gap.
States might also be able to test closed formularies in Medicaid as Trump Administration seeks stronger disincentives for price increases.